Hyperion DeFi (NASDAQ:HYPD) Posts Earnings Results

Hyperion DeFi (NASDAQ:HYPD) issued its quarterly earnings data on Thursday. The company reported ($7.76) EPS for the quarter, FiscalAI reports. The company had revenue of $0.50 million during the quarter.

Hyperion DeFi Stock Performance

Shares of Hyperion DeFi stock opened at $3.49 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.25 and a quick ratio of 2.25. The firm has a market cap of $28.52 million, a price-to-earnings ratio of -0.86 and a beta of 2.74. The stock’s 50-day moving average is $3.47 and its 200-day moving average is $5.32. Hyperion DeFi has a one year low of $0.85 and a one year high of $17.18.

Wall Street Analysts Forecast Growth

HYPD has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Thursday, January 22nd. Cantor Fitzgerald assumed coverage on Hyperion DeFi in a report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 price objective on the stock. Chardan Capital set a $7.75 price objective on Hyperion DeFi and gave the company a “buy” rating in a research report on Wednesday, December 24th. Finally, Zacks Research raised Hyperion DeFi to a “hold” rating in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $5.88.

Insider Transactions at Hyperion DeFi

In other news, Director Ellen R. Strahlman bought 12,112 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were acquired at an average price of $3.60 per share, with a total value of $43,603.20. Following the transaction, the director owned 91,161 shares in the company, valued at $328,179.60. This represents a 15.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David R. Knox purchased 27,950 shares of Hyperion DeFi stock in a transaction on Wednesday, December 31st. The shares were purchased at an average cost of $3.59 per share, with a total value of $100,340.50. Following the transaction, the chief financial officer owned 327,950 shares in the company, valued at approximately $1,177,340.50. The trade was a 9.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 51,918 shares of company stock valued at $186,744. 10.86% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hyperion DeFi

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC bought a new position in Hyperion DeFi during the fourth quarter worth about $38,000. Nations Financial Group Inc. IA ADV acquired a new stake in shares of Hyperion DeFi in the fourth quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD bought a new position in shares of Hyperion DeFi during the 4th quarter worth approximately $73,000. Formidable Asset Management LLC bought a new position in shares of Hyperion DeFi during the 4th quarter worth approximately $83,000. Finally, State Street Corp acquired a new position in shares of Hyperion DeFi during the 4th quarter worth approximately $92,000. 25.84% of the stock is currently owned by institutional investors and hedge funds.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.